Looking Into Novavax's Return On Capital Employed
Portfolio Pulse from Benzinga Insights
Novavax reported Q1 sales of $80.95 million and a loss of $293.90 million, a 61.27% decrease from last quarter. The company posted a return on capital employed (ROCE) of 0.33%, indicating effective capital allocation. Q1 earnings per share were $-3.41, beating analyst predictions of $-3.46.
May 24, 2023 | 2:48 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Novavax's Q1 sales were $80.95 million with a loss of $293.90 million. The company's ROCE of 0.33% indicates effective capital allocation. Q1 earnings per share were $-3.41, beating analyst predictions.
Novavax's Q1 results show a decrease in earnings, but the company's ROCE of 0.33% indicates effective capital allocation. The better-than-expected earnings per share may have a neutral short-term impact on the stock price, as the market may have already priced in the positive news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100